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ABSTRACT
Background: The purpose of this pilot study was to
evaluate the impact of RealHand instruments on laparo-
scopic-assisted vaginal hysterectomy (LAVH) for the treat-
ment of stage I uterine cancer.
Methods: This was a single-center, nonrandomized, con-
secutive patient pilot study. Patient status was evaluated in
terms of operative morbidity, length of surgery, anesthesia
time, body mass index (BMI), estimated blood loss, uter-
ine weight, and hospital stay.
Results: In the group of 10 patients, mean operative time
was 1.7 hours, and anesthesia time was 2.3 hours. Mean
estimated blood loss was 70mL, and patient hospital stay
was 31.8 hours. No intra- or postoperative complications
occurred. Blood loss, anesthesia time, BMI, and uterine
weight were significant predictors of operative time. In
one patient, LAVH using the RealHand instruments was
canceled because of deep pelvic visualization difficulties,
resulting in a conversion to laparotomy.
Conclusion: We present the first reported individual phy-
sician LAVH experience using RealHand instruments for
the treatment of clinical stage I uterine cancer. The re-
ported operative time, reasonable patient complication
rates, and acceptable postoperative stay suggest that these
innovative surgical instruments may have significant
promise in the treatment of patients diagnosed with this
gynecologic disease.
Key Words: RealHand, LAVH, Uterine malignancy, Com-
plications.
INTRODUCTION
Hysterectomy is the second most common surgical pro-
cedure performed in the United States, with nearly
600,000 cases reported annually.1 Laparoscopic hysterec-
tomy was initially reported in 19892 and is frequently
indicated for the treatment of uterine leiomyoma, endo-
metriosis, and uterine prolapse.3 Laparoscopic-assisted
vaginal hysterectomy (LAVH) involves removal of the
uterus and potentially the fallopian tubes, ovaries, or both,
through the vagina. The LAVH procedure is associated
with improved patient outcomes, reduced morbidity, and
shorter hospital stay compared with conventional abdom-
inal surgery,4,5 although some controversy surrounds the
surgical cost and intraoperative complications.6,7
Despite the extensive range of indications for LAVH, phy-
sicians may be constrained by the reduced dexterity and
surgical accessibility associated with this approach.8,9 For
example, conventional laparoscopic devices permit only
up/down and lateral motions potentially impairing access
to uterine vessels. Because inadequate articulation signif-
icantly restricts a surgeon’s visibility and access, determin-
ing the primary surgical route may also be confounded.10
Consequently, innovative technology is being evaluated
in an attempt to significantly enhance a physician’s mo-
bility and range of motion for the surgical treatment of
gynecologic disorders.11
RealHand (Novare Surgical Systems, Cupertino, CA) in-
struments are a novel articulating approach to performing
minimally invasive LAVH. They offer dynamic articulation
with mirrored hand movements (eg, up/down, left/right,
rotation, in/out activation) that extend beyond normal
manipulation within the contained surgical field, thereby
allowing surgeons to utilize the full spectrum of accessi-
bility during laparoscopic operations.
These novel single-use instruments permit full mobility
and tactile feedback within the abdominal cavity, thus
precluding the excessive cost and setup time that is cur-
rently associated with robotic surgical systems. We
present herein the first reported experience evaluating
RealHand instruments for the treatment of clinical stage I
uterine cancer.
Gynecologic Oncology Associates, Hoag Memorial Hospital Cancer Center, New-
port Beach, California, USA (Drs Rettenmaier, Brown, Micha, Goldstein; Ms Lopez,
Graham).
Utah Valley State College, Department of Behavioral Sciences (Dr John).
This study was sponsored by Novare Surgical Systems, Inc. and The Women’s
Cancer Research Foundation.
Address correspondence to: Mark A. Rettenmaier, MD, Gynecologic Oncology
Associates, 351 Hospital Road, Suite 507, Newport Beach, CA 92663, USA. Tele-
phone: 949 642 5165, Fax: 949 646 7157, E-mail: mretten@cox.net
© 2009 by JSLS, Journal of the Society of Laparoendoscopic Surgeons. Published by
the Society of Laparoendoscopic Surgeons, Inc.
JSLS (2009)13:27–31 27
SCIENTIFIC PAPERMETHODS
From May 2007 until December 2007, 12 consecutive stage
I endometrial carcinoma patients were scheduled to un-
dergo LAVH, bilateral salpingo-oophorectomy, and bilat-
eral pelvic lymphadenectomy by an individual gyneco-
logic oncologist. However, 2 patients were excluded from
the study because the Novare surgical representative was
not present at the surgery, and thus a conventional LAVH
was performed. These patients’ data were excluded from
the statistical analyses.
In all patients, uterine malignancy was confirmed via en-
dometrial biopsy, and there were no palpable indications
to initially perform a laparotomy. The patients’ mean age
was 62.4 years (95% CI54.43 to 70.37), height was 63.6
inches (95% CI62.08 to 65.12), and weight was 171.48
pounds (95% CI137.13 to 205.83). Patient mean BMI was
29.7 (95% CI24.11 to 35.25). Four patients were obese,
one was overweight, and 5 were normal weight.12 An
institutional review board approved this study. Patient
consent was obtained prior to any data collection, and
none of the study participants had a prior history of
abdominal surgery.
Preoperative evaluation excluded malignant and prema-
lignant diagnoses in all patients. The participants’ primary
presenting symptoms were pelvic pain, bleeding, and
vaginal discharge. Table 1 exhibits the patients’ final
pathologic diagnosis. Patients were all classified as P2
according to American Society of Anesthesiologists stan-
dards. The following data were collected for the comple-
tion of this study: patient characteristics, blood loss, length
of hospital stay, surgery and anesthesia time, uterine
weight, intraoperative and postoperative complications.
Estimated blood loss was calculated by using total evac-
uated fluid (blood  irrigation) less total irrigation fluid
used.
Instrument
RealHand instruments permit full range of motion and
were developed for minimally invasive laparoscopic sur-
gery. The instruments comprise a cautery, grasper, dissec-
tor, and a ThermaSeal (seals and separates tissue). The
technology is configured to accommodate a surgeon’s
hand direction and movement, while simultaneously pro-
viding concurrent tactile response. The instruments facil-
itate active manipulation and task completion, regardless
of position (ie, over, under, or around structures). There-
fore, when a surgeon’s hand moves to a location, the
instrument’s tip follows suit and facilitates access to more
remote structures. Because the instruments offer 7 degrees
of freedom during movement, a physician is able to per-
form more complex procedures that are normally pre-
cluded by traditional rigid instruments (Figure 1).
Procedure
All patients were initially taken to the operating room and
placed in a supine position. They were then situated in a
dorsal lithotomy position and placed in Allen stirrups,
wherein they were subsequently prepped and draped. A
panel of anesthesiologists elected to use an appropriate
spectrum of anesthetics to induce general anesthesia,
none of which resulted in emesis, nausea, or prolonged
patient hospital stay. Following general anesthesia, a
Foley catheter was inserted transurethrally. Prophylactic
antibiotics were administered, consistent with recommen-
dations for abdominal hysterectomy.13
Twelve-millimeter ports were placed umbilically and su-
prapubically. A 5-mm port was then placed in the right
lower quadrant. The pelvis and abdomen were explored,
with the findings and a single washing submitted for
cytology. Using Harmonic scissors, the surgeon divided
the infundibulo-pelvic ligament, psoas peritoneum, round
ligaments, and vesico-uterine peritoneum. Subsequently,
a bilateral pelvic lymphadenectomy was performed, the
boundaries of which comprised the genito-femoral nerves
laterally, the deep circumflex and iliac veins distally, the
obturator nerves posteriorly, and the umbilical arteries
medially. All lymphatic tissue within these aforesaid
Table 1.
Patients’ Pathologic Diagnosis (N  10)
Patient Histology Stage Grade
1 Endometrial adenocarcinoma 1b 1
2 Endometrial adenocarcinoma 1b 2
3 Endometrial adenocarcinoma w/ clear cell
component
1a 3
4 Endometrial adenocarcinoma 1b 2
5 Endometrial adenocarcinoma w/
mucinous component
1a 2
6 Endometrial adenocarcinoma 3a 1
7 Endometrial adenocarcinoma w/
endometrioid component
1b 2
8 Endometrial adenocarcinoma 1b 1
9 Endometrial adenocarcinoma 1a 1
10 Endometrial adenocarcinoma 1a 1
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pelvic lymph nodes.
The vaginal portion of the procedure was initiated by
infiltrating the circum-cervical vagina with 0.25% Marcaine
with epinephrine and then making a circum-cervical vag-
inal incision. Anterior and posterior cul-de-sacs were en-
tered, and then by using a series of Zeppelin clamps,
pedicles of the utero-sacral ligaments, uterine vessels, and
parametria were developed, divided, and ligated with 2–0
Vicryl until the entire specimen (ie, the uterus, cervix, and
adnexa) was removed. The vagina was then closed with a
baseball stitch via 2–0 Vicryl.
The pneumoperitoneum was reintroduced, and the pelvis
was irrigated with saline. All instruments and trocars were
then removed. The 12-mm port sites and fascia were then
closed with 2–0 Vicryl and 3–0 Monocryl subcuticular
sutures, respectively. All sites were reapproximated with
Dermabond, and the patients were then taken to the
recovery room.
Patients ambulated on the day of surgery. A normal diet
was initiated, and the bladder catheter was removed on
the first postoperative day. Patients were then discharged
from the surgery center after an overnight stay with oral
pain medication.
RESULTS
A statistical analysis (MedCalc; version 9.1) was performed
to evaluate the data from the 10 patients who were the
subject of this study. Mean operative (surgery and setup)
time was 1.7 hours (95% CI1.45 to 1.86), and anesthesia
time was 2.3 hours (95% CI2.05 to 2.48). Mean uterine
weight was 83.4 grams (95% CI55.66 to 111.14). Mean
estimated blood loss was 70 mL (95% CI35.45 to 104.55),
and hospital stay was 31.8 hours (95% CI29.62 to 34.07).
No major or minor intra- or postoperative complications
were encountered with the patient surgeries. Blood loss
was reasonable, and no significant complications or trips
to the emergency room occurred. However, in one of the
surgeries, a patient had a large classified subserosal
leiomyoma that resulted in deep pelvic visualization dif-
ficulties. She experienced both a spontaneous drop in her
oxygen saturation and compromised ventilatory effort.
Consequently, the procedure was converted to laparot-
omy.
In a multivariate regression analysis, we examined the
prognostic impact of blood loss, BMI, and uterine weight
on the length of surgery. The model was significant at
predicting length of surgery (R
20.90; P0.011). We fur-
ther explored these predictor variables to determine their
relationship with length of surgery. The evaluation re-
vealed significant relationships between surgery length
and BMI (r0.80; P0.005), blood loss (r0.70; P0.02),
anesthesia time (r0.92; P0.0001), and uterine weight
(r0.71; P0.02).
We also investigated the prognostic impact of surgery
time, uterine weight, blood loss, and BMI on patient time
in the facility. None of the aforementioned variables sig-
nificantly impacted patient time in the facility (R
20.74;
P0.22).
Figure 1. RealHand grasper manipulating uterine cornu.
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Laparoscopic-assisted vaginal hysterectomy is primarily
indicated for patients with endometriosis, adhesions, and
fibroids.3 Furthermore, the procedure is associated with
low morbidity rates, favorable recovery time, and reduced
pain in comparison with both abdominal hysterectomy
and conventional vaginal hysterectomy.4,5,9 However,
LAVH can be a protracted and complicated surgery be-
cause of reduced dexterity and surgical accessibility dur-
ing the operative course.10
The RealHand surgical instruments were developed to
provide greater surgical dexterity and control when oper-
ating in close proximity to critical structures and vascula-
ture. The capacity for increased range of motion was also
designed to potentially facilitate and enhance intra- and
postoperative surgical outcomes. One may argue that the
dexterity and control of RealHand offer a better solution to
lymphadenectomy, primarily in comparison to LAVH. In
particular, the articulation appears to allow for a more
accurate targeting of nodes.
In terms of cost, we contend that the RealHand is finan-
cially justified because only one instrument per case is
used, in contrast with an entire set. Moreover, the Real-
Hand devices may be substituted for another disposable
instrument that the surgeon typically uses (eg, disposable
scissors). While we did not conduct a cost analysis, we
suspect that the RealHand instruments warrant additional
fiscal consideration because the articulating laparoscopic
capacity increases surgical dexterity without the addi-
tional training and expenses inherent in performing ro-
botic surgery.
In the current study, we present the first surgical experi-
ence of an individual gynecologic oncologist who per-
formed all operations with the RealHand surgical instru-
ments at a single facility. Patient operative time was within
normal limits (1.7 hours) but distinctly less than the 3.7
hours reported by Frigerio et al.14 Initially, we considered
further analyzing patient operative time to discern a pos-
sible learning curve, but we recognize that the results
would be inconclusive due to the small patient popula-
tion. We also acknowledge the difficulty in comparing the
impact of innovative surgical technology because the data
are often confounded by multiple physician involvement,
in-patient care, and institutional variability.15,16
Patient blood loss (70mL) was a significant prognostic
indicator of increased surgery time. However, our rate
was similar to that reported in prior LAVH studies.14,17 We
suggest that the patients’ uterine weight may have resulted
in longer surgery times, although additional LAVH out-
comes studies have not reported analogous findings.4,15,18
Increased BMI appeared to affect operative time, which
was expected considering that 4 of the patients were
obese. Therefore, because obesity may be associated with
more complicated surgeries, corresponding protracted
operative times should be anticipated.19
Patient length of hospital stay (31.8 hours) was similar to
that reported by Gemignani et al,17 but dramatically less
than the 64.8 or 96 hours reported in previous studies.14,20
Bladder, urinary tract, and bowel injuries are frequently
reported complications in LAVH outcome studies,7,21 al-
though none of these conditions manifested themselves in
the present series. Despite the reasonable complication
rate, one patient was converted to laparotomy due to
deep pelvic visualization difficulties.
We recognize that the limited number of patients, absence
of a control population, and nonrandomized nature of this
single-institutional study preclude any definitive conclu-
sions or comparisons with previously reported LAVH
studies. Nevertheless, the results from this study indicate
that these innovative instruments may have significant
promise in the treatment of stage I uterine cancer and
potentially for higher stage uterine cancer procedures.
Additional investigation comparing these surgical devices
with standard instruments in a larger randomized study
involving different uterine cancer populations is war-
ranted.
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